NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
MWN-AI** Summary
NEXGEL, Inc. (NASDAQ: NXGL), a prominent developer of healthcare and consumer products, has rescheduled its conference call to discuss financial results for the fourth quarter and fiscal year 2025. The call will now take place on April 8, 2026, at 4:30 P.M. ET, allowing the company to provide shareholders with more comprehensive details regarding its proposed transaction with Celularity Inc. This adjustment reflects NEXGEL’s intent to ensure that shareholders receive thorough insights into the transaction.
On the same day, the Company will file its Annual Report on Form 10-K for the year ending December 31, 2025, with the U.S. Securities and Exchange Commission. This report is expected to outline the Company's financial performance and strategic direction for the future.
NEXGEL, headquartered in Langhorne, Pennsylvania, specializes in high-water-content hydrogel products, which are utilized in healthcare, beauty, and OTC applications. The Company has over two decades of experience in developing innovative hydrogel solutions and is known for brands like SilverSeal®, Hexagels®, and Turfguard®. The rescheduled conference call aims to keep shareholders informed as NEXGEL strengthens its position in the industry through strategic partnerships, such as the one with Celularity.
Investors and interested parties can participate in the conference call by dialing 1-800-267-6316 for U.S. callers or 1-203-518-9783 for international participants. There will also be a webcast available for those who prefer to access the call online.
NEXGEL’s forward-looking statements underline the company's commitment to transparency, emphasizing potential risks and uncertainties that could influence its outcomes, while encouraging shareholders to review specific risk factors detailed in the forthcoming Form 10-K submission.
MWN-AI** Analysis
NEXGEL, Inc. (NASDAQ: NXGL) has rescheduled its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026, at 4:30 PM ET. This rescheduling is significant as it provides the company time to offer a detailed update regarding its proposed transaction with Celularity Inc. This development warrants careful consideration for current and potential investors.
First, the rescheduling suggests that NEXGEL is prioritizing transparency with its shareholders during a critical phase in its dealings. A focus on providing additional context around the proposed transaction may indicate that the management is keen on addressing investor concerns and heightening confidence in the company’s future trajectory.
Additionally, NEXGEL’s product portfolio—ultra-gentle, high-water-content hydrogel solutions—positions it in a niche market that has potential for growth. The strategic partnership with Celularity could open new avenues, especially in the fields of healthcare and beauty, where innovation is crucial. Shareholders should be keenly aware of the details to emerge from the April 8 call as they could shift market sentiment and influence stock performance.
Moreover, the announcement of the company’s 10-K filing on the same day is an essential signal. A thorough understanding of their financials, including revenue performance and profitability metrics, will be crucial for evaluating the potential success of the Celularity transaction. As the market anticipates this dual disclosure, there may be volatility in NEXGEL’s stock price leading up to the call.
Investors are advised to stay informed and evaluate market reactions post-conference call. They should assess how well the company articulates its strategy and how the transaction might affect shareholder value moving forward. In summary, patience and due diligence will be paramount as NEXGEL navigates this pivotal period.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc.
The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026.
Fourth Quarter and Full Year 2025 Financial Results Conference Call Details:
Date: April 8, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ**
How might the proposed transaction with Celularity Inc. influence the market perception of NexGel Inc Warrant NXGLW, and what should investors consider before the financial results call on April 8, 2026?
What specific details can shareholders expect during the April 8, 2026, conference call that could impact the valuation of NexGel Inc Warrant NXGLW?
What are the anticipated challenges or risks associated with NexGel Inc Warrant NXGLW as outlined in the recently filed Annual Report on Form 10-K for 2025?
In what ways does NexGel's strategic contract manufacturing relationships enhance the potential value of NexGel Inc Warrant NXGLW in light of the fourth quarter financial results?
**MWN-AI FAQ is based on asking OpenAI questions about NexGel Inc (NASDAQ: NXGL).
NASDAQ: NXGL
NXGL Trading
14.42% G/L:
$0.595 Last:
377,697 Volume:
$0.53 Open:
